The CRISPR-Cas9 system has emerged as a highly versatile platform for introducing targeted genome modifications into mammalian cells and model organisms. However, fully capitalizing on the therapeutic potential for this system requires its safe and efficient delivery into relevant cell types. Adenoassociated virus (AAV) vectors are a clinically promising class of engineered gene-delivery vehicles capable of safely infecting a broad range of dividing and nondividing cell types, while also serving as a highly effective donor template for homology-directed repair. Together, CRISPR-Cas9 and AAV technologies have the potential to accelerate both basic research and clinical applications of genome engineering. Here, we present a step-by-step protocol for AAV-mediated delivery of CRISPR-Cas systems into mammalian cells. Procedures are given for the preparation of high-titer virus capable of achieving a diverse range of genetic modifications, including gene knockout and integration.
Dulbecco's modified Eagle's medium (DMEM)
Escherichia coli TOP10 cells (Thermo Fisher Scientific C4040-03) Expand High Fidelity PCR System (Roche 11759078001) Fetal bovine serum (FBS) Gel extraction kit Gel-loading dye (10×) <R> Human embryonic kidney (HEK) 293 T cells (ATCC CRL-1573) iCycler mix (2×) <R> This is needed to make the qPCR master mix.
Iodixanol solution (54%) <R> Iodixanol solutions (15%, 24%, and 40%) <R> LB solid or liquid medium <R> Linear polyethylenimine (PEI) (MW 25,000; Polysciences) MgCl 2 (0.15 M) Oligonucleotides (see Steps 4, 14, 76, and 78) pAAV-Cas9-sgRNA plasmid This is available on request to the authors.
PBS (10×) +/− Tween 20 <R>
Include the appropriate concentration of Tween 20 and dilute if necessary. This protocol requires 1× PBS, 1× PBS containing 0.001% Tween 20, and 1× PBS containing 5% Tween 20.
PBS-MK (10×) <R>
Include the appropriate concentration of NaCl and dilute if necessary. This protocol requires 10× PBS-MK containing 1.37 M NaCl, 1× PBS-MK containing 0.137 M NaCl, and 1× PBS-MK containing 2 M NaCl.
pHelper plasmid (available upon request from the authors) (or plasmid that contains adenovirus helper genes) Polyacrylamide gels Proteinase K (New England Biolabs P8107S) Proteinase K incubation buffer (2×) <R> pXX2 (Cell Biolabs VPK-422) (or plasmid that contains the desired AAV rep and cap genes) qPCR master mix <R> QuickExtract DNA Extraction Solution (Epicentre QE09050) SURVEYOR Mutation Detection Kit, containing Enhancer, Nuclease, and Stop Solution (Integrated DNA Technologies 706021) SYBR Safe (Thermo Fisher Scientific S33102) T4 DNA ligase with buffer (New England Biolabs M0202L) T4 polynucleotide kinase (New England Biolabs M0201L) Terrific broth (TB) medium <R> TBE electrophoresis buffer (10×) <R> Use diluted in distilled water at 1× strength.
Trypsin-EDTA (Thermo-Fisher Scientific 25300054)
Equipment 96-well flat-bottom tissue-culture plate Access to DNA sequencing facilities Benchtop centrifuge Cell-culture plates (15-cm) Cell scraper Conical tubes (sterile, 15-and 50-mL) Freezer set at −20˚C 9. Ligate the sgRNA duplex DNA into 20-50 ng of linearized pAAV-Cas9-sgRNA (empty) using 1 U of T4 DNA ligase for 1 h at room temperature.
A 6:1 molar insert:vector ratio is recommended for ligation.
10. Thaw 100 µL of chemically competent E. coli TOP10 cells on ice and mix gently with ligated pAAV-Cas9-sgRNA.
11. Keep the cells on ice for 30 min. Heat-shock the mixture for 35 sec at 42˚C and recover the cells in 1 mL of lysogeny broth (LB) for at least 30 min at 37˚C with shaking.
12.
Spread 50-100 µL of bacterial cell culture on a LB agar plate with 100 µg/mL ampicillin and incubate overnight at 37˚C.
13.
The following day, inoculate 2-4 mL of terrific broth (TB) medium containing 100 µg/mL ampicillin with one colony from the LB agar plate and culture overnight at 37˚C with shaking.
14. Purify pAAV-Cas9-sgRNA by plasmid miniprep and confirm plasmid identity by DNA sequencing using the primer U6 Seq (5 ′ -GACTGTAAACACAAAGATATTAGTAC-3 ′ ).
15. Test the ability of Cas9 to induce modifications at the genomic target site in mammalian cell culture by transient transfection of pAAV-Cas9-sgRNA using the procedures described in Steps 60-75.
It is strongly recommended that this control be performed. 16. Thaw 100 µL of chemically competent E. coli TOP10 cells on ice and mix gently with 100 ng of pAAV-Cas9-sgRNA plasmid. Transform as above (Steps 10-12).
17. The following day, inoculate 50-100 mL of TB medium containing 100 µg/mL ampicillin with one colony and grow overnight at 37˚C with shaking.
18. Purify plasmid DNA by plasmid midiprep or maxiprep, according to the manufacturer's instructions, or by PEG precipitation.
19. Store plasmid at −20˚C until transfection.
Adeno-Associated Virus Production
20. Maintain HEK293 T cells in DMEM containing 10% (v/v) FBS and 1% antibiotic-antimycotic at 37˚C in a fully humidified atmosphere with 5% CO 2 .
21. Seed HEK293 T cells onto a 15-cm plate at a density of 2.5-3 × 10 7 cells/plate.
22.
At 24 h after seeding, or once cells are~90% confluent, add 15 µg pAAV-Cas9-sgRNA, 15 µg pXX2, and 15 µg pHelper plasmids to 4 mL of cell-culture medium in a sterile 15-mL conical tube.
23.
Add 135 µL PEI (1 µg/µL) and mix immediately by vortexing for 10 sec.
The volume of PEI is based on a 3 to 1 ratio of PEI (µg) to total DNA (µg).
24.
Incubate transfection solution for 10 min at room temperature.
Add transfection solution dropwise to cells.

(Optional)
Change media 8-12 h posttransfection to reduce transfection-reagent-associated toxicity.
27.
Harvest virus from cells 48-72 h posttransfection by manually dissociating cells from plate using a cell scraper and pipetting media and cells into 50-mL conical tubes.
28. Pellet cells by centrifugation at 1500g for 5 min at room temperature.
29.
Remove media and resuspend cells in 2 mL of lysis buffer for each 15-cm plate.
30.
Freeze-thaw cells three times using a dry-ice-ethanol bath and a 37˚C water bath.
The cell lysate can be stored at −20˚C after the third freeze.
31. Incubate the cells with 10 U of benzonase per milliliter of cell lysate. Incubate the samples for 30 min at 37˚C.
32.
Centrifuge cell lysate at 10,000g for 10 min at room temperature.
33. Transfer supernatant to new tubes and store at 4˚C until purification.
Iodixanol Density Gradient Centrifugation
34. Pipette 1.2 mL of 15% iodixanol solution into an OptiSeal polyallomer centrifuge tube.
Ensure that each iodixanol solution contains the appropriate amount of 10× PBS-MK containing 1.37 M NaCl, 1× PBS-MK containing 0.137 M NaCl, or 1× PBS-MK containing 2 M NaCl.
35. Underlay the 15% iodixanol solution with 0.7 mL of 24% iodixanol solution containing phenol red using a long blunt-ended cannula attached to a 3-mL syringe.
36. Underlay the 24% iodixanol solution with 0.6 mL of 40% iodixanol solution.
37. Underlay the 40% iodixanol solution with 0.6 mL of 54% iodixanol solution containing phenol red.
38. Gently pipette 1.8 mL of crude lysate onto each gradient.
39. Weigh tubes to ensure that they are properly balanced. Use AAV lysis buffer to balance tubes as necessary and seal tubes using the caps provided.
40. Set preparative ultracentrifuge to slow acceleration and deceleration settings and centrifuge gradients at 174,000g for 2 h at 18˚C.
41.
Carefully remove centrifuge tubes from the rotor and secure the centrifuge tube in a clamp attached to a ring stand. Remove the cap.
42. Carefully puncture the tube at the interface between the 40% and 50% iodixanol solutions using a 21-gauge 1½ ′′ regular-bevel needle attached to a 1-mL syringe.
43. Collect the bottom four-fifths of the 40% iodixanol solution (bevel up) and the top one-fifth of the 54% iodixanol solution (bevel down) (Zolotukhin et al. 1999 ).
Contaminating proteins from the cell lysate will be present in a band at the interface between the 24% and 40% iodixanol layers. Do not collect the protein band.
44. Store collected fractions in a sterile 1.7-mL microcentrifuge tube or a 15-mL conical tube at 4˚C until further purification.
Buffer Exchange and Concentration
45. Incubate Ultra-15 Centrifugal Filter Unit in 1× PBS containing 5% Tween 20 for 30 min at room temperature. After incubation, wash filter once with 1× PBS containing 0.001% Tween 20.
46. Dilute collected iodixanol fraction to 15 mL in 1× PBS containing 0.001% Tween 20 and add to Ultra-15 Centrifugal Filter Unit.
47. Centrifuge at 4000g for 30 min or until solution has been concentrated to <2 mL.
48. Add 15 mL of 1× PBS containing 0.001% Tween-20 and mix well.
49.
Repeat Steps 47 and 48 three times or until all iodixanol has been eliminated and the viscosity of the solution is similar to that of 1× PBS containing 0.001% Tween 20. 52. Incubate the sample for 10 min at 75˚C to inactivate DNase I.
53. Add 60 µL of 2× proteinase K incubation buffer and 10 µL of proteinase K to virus sample and incubate for at least 1 h at 37˚C.
54. Incubate for 20 min at 95˚C to inactivate the proteinase K.
55.
Create 10-fold serial dilutions of pAAV-SpCas9-sgRNA plasmid between 0.2 ng/µL and 0.02 pg/ µL for generating a standard curve.
Prepare qPCR master mix containing iCycler mix.
57. Dilute virus sample 10-fold for qPCR.
58. Combine 15 µL of qPCR master mix with 5 µL of virus sample or linear plasmid for the standard curve and run qPCR using the following protocol. 69. Denature and re-anneal the PCR amplicon to generate mismatched duplex DNA for the SURVEYOR nuclease assay using the following profile. 72. Load the samples in a PAGE apparatus on a 10%-14% TBE acrylamide gel and run the gel at 140-180 V until the xylene cyanol band from the gel loading dye is located in the middle or bottom third of the gel.
73.
Remove the gel and stain with 10 µL of SYBR Safe in 30 mL of 1× TBE electrophoresis buffer for 10 min. Wash the gel at least once with water.
74. Visualize the gel using a gel imaging system and measure the density or intensity of each band.
75. Determine the percentage gene modification by measuring the fraction of parental band cleaved at the anticipated location, as described previously (Guschin et al. 2010 ).
Gene Targeting
Nuclease-induced double-strand breaks can stimulate integration of donor DNA into an endogenous locus through homology-directed repair (HDR) (Rouet et al. 1994; Bibikova et al. 2001) . AAV, in particular, can enhance gene targeting by >1000-fold compared with plasmid DNA (Russell and Hirata 1998; Jang et al. 2011; Asuri et al. 2012; Gaj et al. 2015) . Optimal homology arm length ranges from 0.5 to 1.5 kb.
To construct AAV vectors for gene targeting, design primers to PCR-amplify
Encode single-base modifications on the 3
′ and 5 ′ ends of the antisense and sense primers of the "left" and "right" homology arms, respectively. Encode a silent restriction site on the donor template for downstream analysis.
78. For gene integration, design a second set of primers to amplify the gene of interest (GOI), with 20-30 nucleotides of sequence complementary to the 3 ′ and 5 ′ ends of the "left" and "right" homology arms, respectively. Ensure that the Cas9 cleavage site is not present in the donor construct.
Because of the carrying capacity of AAV, the donor template should not exceed 4.7 kb.
79. PCR-amplify the homology arms from genomic DNA and the GOI from cDNA or plasmid DNA using the primers designed in Steps 76 and 78.
80. Gel-purify the homology-arm-encoding and GOI-encoding amplicons using a gel extraction kit, according to the manufacturer's instructions. Gibson et al. 2009 ) to generate the donor template.
Fuse the amplicons together by overlap PCR or Gibson assembly (
82. Gel-purify the donor template by gel extraction and digest both it and the AAV plasmid (e.g., AAV-Cas9-sgRNA) with AflII and KpnI restriction enzymes.
83.
Ligate the donor template into 20-50 ng of digested AAV plasmid and transform into cells, as described in Steps 21-26.
84.
Purify the AAV donor plasmid by miniprep and confirm plasmid identity by DNA sequencing.
85. Construct the accompanying AAV-Cas9-sgRNA vector, and package and purify both it and the AAV donor, as described in Steps 20-59.
Infect cells with purified AAV vectors, as described in Steps 60-62.
Cells infected with AAV donor vector containing a selectable marker, such as a puromycin-resistance gene or enhanced green fluorescent protein (EGFP), can be subjected to antibiotic selection or harvested for fluorescence-activated cell sorting (FACS) at 72 h after infection. Limiting dilution is recommended for isolation and expansion of clonal cell lines.
87. Isolate genomic DNA, as described in Steps 63-66, and PCR-amplify the genomic target across the integration junctions using the Expand High Fidelity PCR System. If the donor template contained a silent restriction site, evaluate the integration frequency by restriction digestion analysis. Determine gene modification by measuring the fraction of the parental band cleaved at the anticipated location. Finally, use DNA sequencing to confirm the presence of gene modifications.
See Troubleshooting.
TROUBLESHOOTING
Problem (Step 59):
The calculated titer value is too low. Solution: A low titer can arise for a number of reasons, including using an impure plasmid preparation, mutations within the AAV plasmid from modification of inverted terminal repeats, toxicity from PEI transfection, off-target cleavage within the AAV vector genome by Cas9, or the vector being released from cells. Possible solutions include using phenol-chloroform extraction of the AAV plasmid to improve vector purity, diagnostic restriction digestion of the AAV vector to establish vector integrity, transfection by calcium phosphate to eliminate the possibility of PEIinduced toxicity, and harvesting the cells 48 h after transfection.
Problem (
Step 63): Infectivity is low. Solution: Because of differences in primary receptor usage and capsid composition, many naturally occurring AAV vectors display differential infection abilities both in vitro and in vivo. Therefore, the use of AAV vectors with the intended cell or tissue tropism is essential for efficient gene delivery. Infection by AAV serotypes can be measured by using a fluorescent reporter gene, such as that encoding EGFP. Engineered or evolved AAV vectors with improved or altered tropism can also be used to enhance infection (Kotterman and Schaffer 2014) .
Problem (Step 75):
The efficiency of genome modification is low. Solution: Poor genome modification could be due to a number of factors, including low levels of Cas9-mediated cleavage at the genomic target site, terminal truncations within the AAV vector genome, and low levels of Cas9 expression. Test the ability of the Cas9-sgRNA complex to induce modifications at the genomic target by transient transfection. Because of the limited carrying capacity of AAV, packaging a single vector containing both a large Cas9 variant (such as SpCas9) and sgRNA could lead to vectors with truncations at the 5 ′ end of the vector genome (Senis et al. 2014) . Use Southern blot analysis to establish whether truncations are present. To minimize vector genome heterogeneity, SpCas9 and sgRNA can be delivered using two separate particles (Swiech et al. 2015) . Smaller Cas9 orthologs, such as Neisseria meningitidis (NmCas9) (Hou et al. 2013) and SaCas9 (Ran et al. 2015) , can also be used to induce genome modifications from a single AAV particle despite their more restrictive PAM requirements. Finally, confirm that the promoter is providing high levels of expression in the desired cell type by western blotting or by the use of a fluorescent reporter gene, such as one encoding EGFP.
Problem (Step 87):
The efficiency of integration is low. Solution: No integration could be the result of insufficient homology arm length, low levels of Cas9 activity, or poor infectivity. Test the ability of the Cas9-sgRNA complex to induce modifications at the genomic target by transient transfection. Use an alternative sgRNA if activity is low. In addition, test the ability of the AAV donor vector in combination with Cas9 to mediate HDR by transient transfection. Modify homology arm length in cases where the existing donor template does not trigger integration. Use of small molecules that inhibit nonhomologous end joining (NHEJ) can also enhance HDR (Chu et al. 2015; Wurst et al. 2015; Yu et al. 2015) . Sterilize using a disposable 0.22-µm vacuum filtration system in a tissue-culture hood and store at room temperature.
RECIPES
AAV Lysis Buffer
